Evgenia Alpert

Title: Evgenia Alpert: Innovator in Nucleic Acid Delivery and Eye Disorder Treatments

Introduction

Evgenia Alpert is a prominent inventor based in Jerusalem, Israel, known for her significant contributions to the fields of biotechnology and medicine. With a total of six patents to her name, she has made remarkable advancements in the delivery of nucleic acids and the treatment of eye disorders.

Latest Patents

One of her latest patents is titled "Lipidated glycosaminoglycan particles for the delivery of nucleic acids." This invention provides compositions that comprise lipidated glycosaminoglycan particles, along with methods for their preparation and uses for the efficient in-vivo and in-vitro delivery of nucleic acids, such as siRNA molecules. Another notable patent is focused on "Methods for treating eye disorders." This invention relates to compositions and methods aimed at inhibiting the loss of retinal ganglion cells in subjects. It involves non-invasively applying an ophthalmic composition containing a therapeutically effective amount of siRNA that down-regulates the expression of target genes associated with retinal ganglion cell loss.

Career Highlights

Evgenia Alpert has worked with notable organizations, including Quark Pharmaceuticals, Inc. and Ramot at Tel-Aviv University Ltd. Her work in these companies has allowed her to develop innovative solutions that address critical health issues.

Collaborations

Throughout her career, Evgenia has collaborated with esteemed colleagues, including Igor Spivak and Elena Feinstein. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Evgenia Alpert's work exemplifies the impact of innovation in biotechnology and medicine. Her patents not only enhance the understanding of nucleic acid delivery but also offer promising solutions for treating eye disorders.